📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
0 analysed today
FollowTelegram
0
Today
152,139
All-time analysed
43,645
Positive
6,747
Negative
92,898
Neutral
8,781
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
47 announcements match the current filters (relevance ≥ 5).
KIMS Closes QIP Raising ~₹1,500 Crore via Allotment of 1.98 Cr Shares at ₹755/Share
Krishna Institute of Medical Sciences (KIMS) has successfully concluded its Qualified Institutions Placement (QIP) which opened on June 16, 2026. The company approved the allotment of 19,867,549 equity shares to eligible institutional buyers at a price of ₹755 per share. This issue price includes a discount of 2.17% (₹16.73 per share) on the floor price. The total capital raised through this exercise is approximately ₹1,500 crore, which is expected to bolster the company's expansion plans or debt profile.
Key Highlights
Allotment of 19,867,549 equity shares of face value ₹2 each to qualified institutional buyers.
Issue price fixed at ₹755 per share, including a premium of ₹753 per share.
The final price represents a 2.17% discount (₹16.73) to the floor price of the issue.
The QIP process was completed within four days, opening on June 16 and closing on June 19, 2026.
Total fundraise amount is approximately ₹1,500 crore based on the approved allotment.
👀 What to Watch
Investors should monitor the company's upcoming disclosures regarding the specific utilization of these funds, as successful institutional fundraising typically signals strong confidence in the hospital chain's growth trajectory.
KIMS Launches QIP with Floor Price of ₹ 771.73 per Share
Krishna Institute of Medical Sciences (KIMS) has announced the opening of its Qualified Institutions Placement (QIP) on June 16, 2026. The Finance & Investment Committee has fixed the floor price at ₹ 771.73 per equity share, calculated as per SEBI regulations. The company may offer a discount of up to 5% on this floor price at its discretion. A meeting is scheduled for June 19, 2026, to finalize the issue price for the equity shares.
Key Highlights
QIP issue officially opened on June 16, 2026, following board and shareholder approvals.
Floor price for the issue set at ₹ 771.73 per equity share based on SEBI ICDR regulations.
Company authorized to offer a discount of up to 5% on the calculated floor price.
Finance & Investment Committee meeting scheduled for June 19, 2026, to determine the final issue price.
Trading window for designated persons is closed from June 16, 2026, until 48 hours after price determination.
👀 What to Watch
Investors should monitor the final issue price and the discount offered on June 19, as high institutional demand often signals confidence in the company's growth trajectory.
KIMS Submits Audited FY26 Financial Statements; Auditor Confirms No Material Uncertainties
Krishna Institute of Medical Sciences (KIMS) has filed its full audited standalone and consolidated financial statements for the year ended March 31, 2026. The statutory auditor, S.R. Batliboi & Associates LLP, issued a clean report with no qualifications or adverse remarks. The company confirmed it incurred no cash losses in the current or preceding financial year and maintains adequate internal financial controls. Notably, the auditor stated there is no material uncertainty regarding the company's ability to meet its liabilities within the next 12 months.
Key Highlights
Statutory auditors issued an unmodified opinion on both standalone and consolidated FY26 financial statements.
The company and its subsidiaries reported no cash losses for the current and immediately preceding financial years.
Auditors confirmed the effective operation of the 'audit trail' (edit log) feature in accounting software throughout the year.
No dividend was declared or paid by the Holding Company or its subsidiaries for the financial year ended March 31, 2026.
Management and auditors confirmed no material uncertainty exists in meeting liabilities falling due within one year.
👀 What to Watch
This is a routine compliance filing following the initial results announcement in May. Investors should focus on the full annual report for detailed operational metrics and growth guidance, as the company is currently prioritizing capital retention over dividends.
KIMS Board Approves ₹600 Crore Fundraise via Preferential Issue of Warrants to Promoters
The Board of Krishna Institute of Medical Sciences (KIMS) has approved the issuance of 77,02,182 warrants to its promoters and promoter group at a price of ₹779 per warrant. This preferential allotment aims to raise approximately ₹600 crore, with 25% of the issue price payable upfront and the remaining 75% within 18 months upon conversion into equity shares. Post-conversion, the total promoter and promoter group holding is projected to increase from 34.11% to 35.35%. An Extra-Ordinary General Meeting (EGM) is scheduled for July 9, 2026, to obtain shareholder approval for this proposal.
Key Highlights
Approved issuance of 77,02,182 convertible warrants at a price of ₹779 per warrant (including ₹777 premium).
Total fundraise aggregates to approximately ₹599.99 crore from the promoter group.
Promoter and Promoter Group shareholding to increase from 34.11% to 35.35% assuming 100% conversion.
Warrants are convertible into equity shares of face value ₹2 each within a period of 18 months.
Extra-Ordinary General Meeting (EGM) for shareholder approval is scheduled for July 9, 2026.
👀 What to Watch
Investors should view this as a positive signal of promoter commitment and confidence in the company's long-term growth. Monitor the EGM outcome and the company's subsequent plans for utilizing the ₹600 crore capital infusion.
KIMS Q4 FY26 Revenue Jumps 35% to ₹1,084 Cr; PAT Declines Amid Aggressive Expansion
KIMS reported a robust 35.3% YoY revenue growth in Q4 FY26, reaching ₹1,084 crore, driven by new unit contributions and steady performance in mature hospitals. However, consolidated PAT saw a sharp decline to ₹33 crore from ₹106 crore YoY, primarily due to high gestation costs and a ₹32 crore EBITDA erosion from newly commissioned units. While mature units maintain healthy EBITDA margins of ~29%, the overall consolidated margin compressed to 19.9%. Management indicated a forthcoming QIP in the next 1-2 months to support its ongoing capital requirements and expansion strategy.
Key Highlights
Q4 FY26 Revenue grew 35.3% YoY to ₹1,084 crore, while full-year FY26 revenue reached ₹3,931 crore.
Consolidated EBITDA margin compressed to 19.9% in Q4 FY26 compared to 25.3% in the previous year.
Mature units contributed ₹862 crore in revenue with a steady EBITDA margin of approximately 28.5-29%.
Operational metrics remained strong with ARPOB growing 13.7% YoY and IP volumes increasing by 17.9%.
New units in Nashik, Thane, and Karnataka contributed ₹224 crore to revenue but resulted in a combined EBITDA loss of ₹32 crore.
👀 What to Watch
Investors should monitor the break-even trajectory of the new clusters in Bangalore and Maharashtra, as their ramp-up is critical for margin recovery. The planned QIP suggests further growth intent but may lead to near-term equity dilution.
KIMS Q4 FY26 Revenue Up 35% to ₹1,084 Cr; PAT Drops 69% Due to Expansion Costs
KIMS reported a robust 35.3% YoY revenue growth in Q4 FY26, reaching ₹1,084 Cr, driven by strong volume growth in both inpatient (17.9%) and outpatient (30.1%) segments. However, net profit (PAT) for the quarter plummeted 68.9% YoY to ₹33 Cr, primarily due to higher interest and depreciation costs associated with new hospital units. EBITDA margins contracted significantly to 19.9% from 25.3% a year ago. For the full year FY26, revenue grew 28.2% to ₹3,931 Cr, while PAT fell 41.7% to ₹242 Cr.
Key Highlights
Q4 FY26 Total Revenue grew 35.3% YoY to ₹1,084 Cr, while FY26 Revenue rose 28.2% to ₹3,931 Cr.
Q4 PAT declined sharply to ₹33 Cr from ₹106 Cr in Q4 FY25, impacted by a 155% surge in interest costs.
EBITDA margins for Q4 FY26 stood at 19.9%, down from 25.3% in the same quarter last year.
Operational metrics remained strong with ARPOB growing 13.7% YoY to ₹47,132 and IP volumes up 17.9%.
Company expanded its footprint with 4 new units and plans to increase bed capacity to over 8,600.
👀 What to Watch
Investors should monitor the turnaround time and occupancy levels of the newly launched units in Bengaluru, Kerala, and Thane, which are currently dragging down margins. While the top-line growth is healthy, the stock may remain range-bound until profitability improves post-gestation of these new assets.
KIMS Unveils National Expansion Roadmap to 8,600+ Beds in FY26 Investor Presentation
Krishna Institute of Medical Sciences (KIMS) has detailed its strategic transition from a regional leader to a national healthcare provider, targeting a total capacity of over 8,600 beds. The company is aggressively expanding into Maharashtra, Kerala, Karnataka, and Tamil Nadu, with major projects like Thane (300 beds) and Bangalore (800 beds) slated for 2026. Institutional confidence is high, with DIIs and FIIs collectively holding 49.1% of the equity. The group continues to lead in high-end clinical segments, including organ transplants and the largest ECMO program in India.
Key Highlights
Targeting a total bed capacity of 8,600+ across 6 states, significantly expanding from its original base.
Major 2026 expansion pipeline includes Thane (300 beds), Kollam (320 beds), and Bangalore (800 beds across two units).
Strong institutional backing with DII holding at 32.7% and FII holding at 16.4%.
Maintains clinical leadership as the #1 player in organ transplantation and operates India's largest ECMO program with 18 machines.
Promoter holding remains stable at 34.1% as of March 31, 2026.
👀 What to Watch
Investors should monitor the execution and commissioning timelines of the Thane and Bangalore projects as they are key drivers for future revenue. The strong institutional interest and clear expansion roadmap make it a key stock to watch in the healthcare sector.
KIMS Re-designates Adwik Bollineni as Executive Director and Identifies Key Senior Management
Krishna Institute of Medical Sciences (KIMS) has re-designated Mr. Adwik Bollineni from a Non-Executive to an Executive Director, signaling a more active role for the promoter family member. The company also formally identified three key officials—the CFO, Company Secretary, and Chief Risk Officer—as Senior Management Personnel (SMP) to strengthen its leadership structure. Mr. Sachin Ashok Salvi (CFO) brings over 21 years of finance experience, while Mrs. Nagajayanthi J.R (CS) has over 25 years of legal and compliance expertise. Additionally, Sagar & Associates has been appointed as the Cost Auditor for the 2026-27 financial year.
Key Highlights
Mr. Adwik Bollineni re-designated as Executive & Non-Independent Director effective May 15, 2026
Mr. Sachin Ashok Salvi (CFO) identified as SMP with 21+ years of experience in finance and IPO processes
Mrs. Nagajayanthi J.R (CS) and Mr. Bhaskar Reddy R. K (CRO) formally designated as Senior Management Personnel
M/s. Sagar & Associates appointed as Cost Auditors for the financial year 2026-27
Mr. Adwik Bollineni is the son of CMD Dr. B. Bhaskara Rao and brother of CEO Dr. Abhinay Bollineni
👀 What to Watch
Investors should view this as a formalization of the leadership hierarchy and promoter involvement; no immediate action is required as these are largely internal governance updates.
KIMS FY26 Net Profit Rises 9.6% to ₹295 Cr; Q4 Net Profit Up 14% YoY
Krishna Institute of Medical Sciences (KIMS) reported a steady financial performance for the fiscal year ended March 31, 2026. Standalone total income for FY26 grew to ₹13,001 million compared to ₹11,881 million in FY25, while annual net profit increased by 9.6% to ₹2,951 million. The fourth quarter showed stronger momentum with a 14.2% YoY increase in net profit to ₹771 million. Alongside results, the company strengthened its leadership by appointing a new CFO and re-designating Adwik Bollineni as an Executive Director.
Key Highlights
Standalone Total Income for FY26 reached ₹13,001 million, up 9.4% from ₹11,881 million in FY25.
Q4 FY26 Net Profit grew 14.2% YoY to ₹771 million versus ₹675 million in the same quarter last year.
Full-year Basic Earnings Per Share (EPS) increased to ₹36.88 from ₹33.66 in the previous year.
Mr. Sachin Ashok Salvi appointed as Chief Finance Officer (CFO) as part of senior management expansion.
Mr. Adwik Bollineni re-designated from Non-Executive to Executive Director to take a more active role.
👀 What to Watch
Investors should view the consistent mid-teen growth in quarterly profits and management strengthening as a sign of operational stability. The stock remains a solid long-term hold in the hospital sector.
KIMS Q4 FY26 Standalone Net Profit Rises 25.6% YoY to ₹77.25 Cr; New CFO Appointed
Krishna Institute of Medical Sciences (KIMS) reported a robust performance for Q4 FY26, with standalone net profit climbing to ₹77.25 crore from ₹61.51 crore in the previous year. Total income for the quarter reached ₹353.04 crore, representing a significant growth over the ₹300.11 crore reported in Q4 FY25. For the full financial year 2026, the company achieved a total income of ₹1,340.71 crore and a net profit of ₹284.51 crore. Alongside the results, the board announced key leadership changes, including the appointment of Sachin Ashok Salvi as CFO and the transition of Adwik Bollineni to an Executive Director role.
Key Highlights
Standalone Net Profit for Q4 FY26 grew 25.6% year-on-year to ₹77.25 crore.
Total Income for the full financial year 2026 increased to ₹1,340.71 crore from ₹1,154.72 crore in FY25.
Earnings Per Share (EPS) for the quarter improved to ₹9.65, up from ₹8.44 in the preceding quarter.
Appointed Sachin Ashok Salvi as Chief Financial Officer (CFO) and Bhaskar Reddy R. K as Chief Risk Officer.
Adwik Bollineni re-designated from Non-Executive Director to Executive Director to take a more active role.
👀 What to Watch
The strong double-digit growth in profit and revenue reflects healthy operational performance in the healthcare segment. Investors should view the management strengthening and consistent financial trajectory as positive indicators for long-term growth.
KIMS to Build 500-Bed Multi-Specialty Hospital in Amaravati via 60-Year Land Lease
Krishna Institute of Medical Sciences (KIMS) has entered into a 60-year long-term lease agreement with the Andhra Pradesh Capital Region Development Authority (APCRDA) for 2 acres of land in Amaravati. The company plans to develop a state-of-the-art 500-bed multi-specialty hospital on this site. This facility will provide comprehensive tertiary and quaternary care across specialties like cardiology, oncology, and organ transplants. This expansion strategically positions KIMS to capture healthcare demand in the developing capital region of Andhra Pradesh.
Key Highlights
Secured 2 acres of land in Amaravati on a long-term lease of 60 years from APCRDA.
Planned development of a new 500-bed multi-specialty hospital facility.
Focus on high-end clinical capabilities including oncology, neurosciences, and organ transplants.
Strategic move to address the lack of advanced healthcare infrastructure in the Amaravati region.
Expansion strengthens KIMS's dominant position in the Andhra Pradesh healthcare market.
👀 What to Watch
Investors should monitor the capital expenditure plans and construction timeline for this project as it will significantly add to the company's long-term bed capacity. The move is a positive indicator of KIMS's growth strategy in its core geographic market.
KIMS Partners with Renova for Strategic Clinical Collaboration in Oncology
Krishna Institute of Medical Sciences (KIMS) has entered into a non-commercial brand association agreement with Dakshayani Healthcare Services (Renova), a specialized oncology organization. The partnership focuses on sharing proprietary clinical protocols, cancer research expertise, and academic supervision to enhance patient care. While the agreement is non-commercial, it aims to strengthen KIMS's oncology service standards and brand reputation. This strategic move is expected to improve clinical outcomes and service quality across KIMS's healthcare network.
Key Highlights
Strategic MoU signed with Renova for oncology clinical expertise and research protocols.
Collaboration is non-commercial, focusing on brand association and knowledge sharing.
Renova brings extensive experience in managing cancer centers and specialized treatment methodologies.
The association is expected to contribute positively to KIMS's overall service quality and reputation.
👀 What to Watch
This is a positive development for long-term brand building and clinical excellence; investors should monitor if this leads to increased market share in the oncology segment.
KIMS Shareholders Approve Fundraise via QIP with 99.99% Majority
Shareholders of Krishna Institute of Medical Sciences (KIMS) have overwhelmingly approved a special resolution to raise funds through a Qualified Institutions Placement (QIP). The voting results show near-unanimous support, with 28.37 crore votes in favor and only 26 votes against. Public institutional investors demonstrated high conviction, casting 16.48 crore votes entirely in favor of the proposal. This approval provides the company with the necessary mandate to proceed with capital infusion for its growth or debt management strategies.
Key Highlights
Special resolution for equity issuance via QIP passed with 99.99% majority support.
Total of 28,36,95,628 votes were polled during the postal ballot process ending April 15, 2026.
Public Institutions cast 16,47,96,564 votes, representing 87.39% of their holding, all in favor.
Promoter and Promoter Group supported the resolution with 11,06,94,350 votes in favor.
The resolution is deemed passed as of April 15, 2026, the final date of e-voting.
👀 What to Watch
Investors should watch for the official launch of the QIP to assess the issue price and the extent of equity dilution. The strong institutional support is a positive signal regarding the company's future expansion plans and management's credibility.
KIMS Signs 20-Year O&M Agreement for 210-Bed Hospital in Palakkad, Kerala
KIMS, through its subsidiary KIMS Swastha, has entered into a 20-year definitive agreement to operate and manage the 210-bedded Avitis Super Speciality Hospital in Palakkad, Kerala. The arrangement follows an asset-light model where KIMS will pay a revenue fee of either 4% of net revenues or a minimum guarantee of ₹22 lakhs per month. KIMS will provide a security deposit of ₹29.75 crore, of which ₹24.75 crore is recoverable from future fees over time. Notably, the agreement includes a call option allowing KIMS to acquire a majority stake in the hospital at its discretion.
Key Highlights
20-year Operations and Management (O&M) agreement for a 210-bedded facility in Palakkad.
Revenue fee structure set at the higher of ₹22 Lakhs per month or 4% of Net Revenues.
Total security deposit of ₹29.75 Crore, with ₹24.75 Crore recoverable from monthly fees.
Strategic call option included to acquire a majority share in Avitis Super Speciality Hospitals.
Asset-light expansion strategy to strengthen KIMS brand presence in the Kerala market.
👀 What to Watch
Investors should view this as a positive, low-risk expansion move that broadens KIMS's geographic footprint. Monitor the operational ramp-up of the Palakkad unit and any future announcements regarding the exercise of the majority stake acquisition option.
KIMS Seeks Shareholder Approval to Raise Up to ₹1,500 Crore via QIP
Krishna Institute of Medical Sciences (KIMS) has issued a postal ballot notice to seek shareholder approval for raising capital up to ₹1,500 crore. The funds are proposed to be raised through a Qualified Institutions Placement (QIP) by issuing equity shares to institutional investors. The company may offer a discount of up to 5% on the floor price determined by SEBI regulations. The e-voting process for this special resolution is scheduled to conclude on April 15, 2026.
Key Highlights
Proposed fundraising of up to ₹1,500 crore through a Qualified Institutions Placement (QIP).
Shareholder approval sought via special resolution with e-voting ending April 15, 2026.
Company authorized to offer a discount of up to 5% on the SEBI-calculated floor price.
Minimum 10% of the QIP securities to be allotted specifically to mutual funds.
Allotment of shares must be completed within 365 days from the date of the resolution passing.
👀 What to Watch
Investors should watch for the QIP floor price and the specific utilization plan for the ₹1,500 crore, as it likely signals further hospital acquisitions or greenfield expansions. While the move will result in equity dilution, it provides the necessary liquidity for KIMS to maintain its growth trajectory.
KIMS Board Approves Fundraise of up to ₹1,500 Crores via QIP
The Board of Directors of Krishna Institute of Medical Sciences (KIMS) has approved a proposal to raise funds up to ₹1,500 Crores. The capital will be raised through the issuance of equity shares via Qualified Institutions Placement (QIP) or other permissible modes in one or more tranches. The company is seeking shareholder approval for this move through a postal ballot process. This significant fundraise suggests potential plans for inorganic growth, hospital expansions, or strengthening the balance sheet.
Key Highlights
Approved raising an aggregate amount not exceeding ₹1,500 Crores.
Fundraising to be executed via Qualified Institutions Placement (QIP) or other equity modes.
Board has authorized the Finance & Investment Committee to decide specific terms and conditions.
Approval of postal ballot notice to seek necessary shareholder consent for the issuance.
The meeting commenced at 12:00 Noon and concluded at 1:20 PM on March 11, 2026.
👀 What to Watch
Investors should watch for the QIP floor price and the specific allocation of funds toward expansion or debt reduction. While equity dilution is expected, the scale of the fundraise indicates aggressive growth plans for the hospital chain.
KIMS Q3 FY26: Revenue Crosses ₹1,000 Cr Milestone; Margins Contract to 20.4% on New Unit Drags
KIMS reported a record-breaking quarter with total revenue crossing ₹1,003 crores, a 29.2% YoY increase driven by aggressive expansion. However, consolidated PAT declined significantly to ₹52 crores from ₹93 crores YoY, primarily due to gestation losses from seven new hospitals launched in 2025. Management expects the Thane and Bangalore units to reach EBITDA neutrality by Q1 FY27, which should trigger margin recovery. Operational metrics remain robust with ARPOB growing 20.5% YoY, supported by high-value transplant procedures in new clusters.
Key Highlights
Total revenue reached ₹1,003 crores, marking a 29.2% YoY growth and crossing the ₹1,000 Cr quarterly mark for the first time.
EBITDA margins compressed to 20.4% from 25.9% YoY due to operational costs of 7 new units launched across 5 states.
Average Revenue Per Operating Bed (ARPOB) grew by 20.5% YoY, significantly aided by 25 transplants in the new Bangalore unit.
Consolidated PAT fell 44% YoY to ₹52 crores, resulting in a diluted EPS of ₹1.3 compared to ₹2.16 in the previous year.
Andhra cluster volumes were temporarily impacted by a one-month strike related to the Aarogyasri scheme, though recovery was noted in January.
👀 What to Watch
Investors should focus on the EBITDA break-even trajectory of the new Bangalore and Thane units over the next two quarters. While the current PAT decline reflects heavy expansion costs, the strong ARPOB growth suggests high-quality asset utilization that could drive significant operating leverage once units stabilize.
KIMS Reports FY25 Revenue of ₹3,067 Cr and Expands Network to 18 Hospitals
KIMS released its Q3 and 9M FY26 investor presentation, highlighting a strong growth trajectory with total revenue reaching ₹3,067 crore in FY25. The hospital network expanded significantly from 12 units in 2024 to 18 units in 2025, reflecting aggressive geographic expansion across South and West India. EBITDA grew to ₹759 crore in FY25, maintaining a robust long-term CAGR of 29.7%. The company is targeting a total bed capacity of over 9,100 beds through upcoming projects in locations like Kompally and Gachibowli.
Key Highlights
Total revenue grew to ₹30,670 million in FY25, representing a 26.9% CAGR since 2005
EBITDA reached ₹7,590 million in FY25 with a healthy long-term CAGR of 29.7%
Hospital network expanded from 12 to 18 units within a single year between 2024 and 2025
Future roadmap targets a massive capacity of 9,100+ beds across Telangana, AP, Maharashtra, and Kerala
Strong institutional backing with DIIs and FIIs holding a combined 49.3% stake as of December 2025
👀 What to Watch
Investors should monitor the operational ramp-up and occupancy levels of the 6 newly added hospitals, as they will be the primary drivers for revenue growth in FY26-27. The company's consistent 29%+ EBITDA CAGR makes it a high-quality growth play in the healthcare sector.
KIMS Q3 FY26: Revenue Crosses ₹1,000 Cr Milestone; PAT Drops 44% YoY to ₹52 Cr
KIMS reported a strong 26.9% YoY revenue growth, crossing the ₹1,000 crore quarterly milestone for the first time. However, profitability was significantly impacted by the operationalization of new units, with PAT declining 44% YoY to ₹52 crore and EBITDA margins contracting to 20.4% from 25.9%. Operational metrics remained robust as ARPOB grew by 20.5% YoY, indicating better realization per bed. The management remains optimistic as new units in Bangalore and Thane continue to ramp up clinical and non-clinical parameters.
Key Highlights
Total Revenue reached ₹1,003 Cr, growing 26.9% YoY and 3.9% QoQ.
PAT declined to ₹52 Cr from ₹93 Cr in the previous year, a 44% drop.
EBITDA margins compressed to 20.4% compared to 25.9% in Q3 FY25 due to costs from newer units.
ARPOB (Average Revenue Per Occupied Bed) showed strong growth of 20.5% YoY.
The group currently operates 7,100+ beds with plans to expand to 9,100+ beds.
👀 What to Watch
Investors should monitor the break-even timeline for the new units in Bangalore and Thane, as their current drag on margins is the primary concern. The strong top-line growth and ARPOB improvement suggest healthy underlying demand, making this a long-term play once margins stabilize.
KIMS to Invest ₹100 Crore to Increase Stake in Subsidiary Sunshine Hospital
The Board of KIMS has approved an additional investment of up to ₹100 Crores to acquire further shares in its material subsidiary, Sarvejana Healthcare Private Limited (Sunshine Hospital). KIMS currently holds a 75.53% stake in the subsidiary, which has shown strong financial performance with turnover growing from ₹419.44 Cr in FY23 to ₹597.00 Cr in FY25. The acquisition will be executed in one or more tranches from minority shareholders via cash consideration. This strategic move aims to consolidate ownership in a key performing asset specializing in orthopedics and high-end healthcare.
Key Highlights
Board approved ₹100 Crore investment to buy out minority shareholders in Sunshine Hospital.
Sunshine Hospital turnover grew 28.6% year-on-year to ₹597.00 Cr in FY25.
KIMS currently owns 75.53% of the subsidiary and seeks to further enhance this shareholding.
The acquisition will be funded through cash based on independent valuation reports.
Sunshine Hospital is a key asset for KIMS, focusing on high-growth segments like orthopedics and transplants.
👀 What to Watch
Investors should view this as a positive consolidation of a high-growth subsidiary. Monitor the final acquisition price and the resulting impact on consolidated net profit margins.
